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1. Evidence-based guidelines for the 
management
1.1. Introduction
For all diseases, diagnosis and treatment should 
follow evidence-based guidelines for management [1]. 
Prospective clinical trials are the most important source 
of scientific evidence. Management according to the 
guidelines is more effective and safe for patients, allows 
to compare the results obtained in various centers and 
assess the quality of diagnostic and therapeutic proce-
dures, as well as it is important in terms of didactics.
1.2. Principles of creating guidelines for 
management
The results of properly designed and conducted 
clinical trials represent the most important element of 
guidelines development. The evaluation of research 
results should be comprehensive and take into consi-
deration a variety of priority conditions. The results 
of phase III clinical trials with similar assumptions or 
their meta-analyses are of the greatest value. In special 
epidemiological justified situations (low cancer inci-
dence rate), the results of non-randomized prospective 
studies or eventually observations from retrospective 
comparative studies and case reports may be valuable.
The analyzed prospective studies should use appro-
priate methods in control groups, it is also advisable to 
adopt clinically relevant main objectives of the research. 
Subgroup analyzes should be pre-planned (retrospective 
analyzes are less valuable). It is important to use ade-
quate assumptions for statistical analyzes. The efficacy 
and safety of the assessed intervention should be equally 
evaluated (including the frequency and severity of adver-
se events [AEs] and toxicity-related treatment disconti-
nuation rate). Determination of the impact on patients’ 
quality of life (QoL) is specifically related to safety and 
particularly plays a role in palliative management.
An example of a comprehensive evaluation is laun-
ched by the European Society of Medical Oncology 
(ESMO) the ESMO — Magnitude of Clinical Benefit 
Scale (ESMO-MCBS) [2]. ESMO-MCBS classifies the 
value and clinical benefits of anti-cancer therapies based 
on the effect on survival rates, objective response rates, 
frequency of AEs and quality of life, and relates these pa-
rameters to the results obtained with standard treatment. 
However, radical and palliative treatment methods should 
be classified separately. The assessment of these parame-
ters allows to determine the magnitude of clinical benefit 
and is the basis for reimbursement decisions-making. The 
algorithm for assessing the value of anticancer drugs was 
also developed by the Polish Society of Clinical Oncology 
(PTOK) and the Polish Society of Oncology (PTO) [3].
1.3. Level of evidence and strength of 
recommendation
International scientific societies (e.g. the American 
Society of Clinical Oncology — ASCO or the National 
Comprehensive Cancer Network — NCCN in the 
United States) and institutions evaluating new medical 
technologies (e.g. the National Institute for Health 
and Care Excellence — NICE in the United Kingdom) 
incorporates different methods to classify the quality 
of the evidence and the strength of recommendation 
used for the development of guidelines that apply to 
most patients. All classifications indicate, however, that 
when establishing guidelines, it is important to be aware 
of the occurrence of situations requiring an individual 
approach, taking into account all medical and socio-
-economic conditions. An example of individualization 
in the guideline development process is establishing the 
rules of management for patients with advanced age 
or concurrent, non-cancer, serious medical conditions.
The PTOK guidelines for the diagnostic and the-
rapeutic management assume 4 levels of the quality of 
scientific evidence (I, II, III and IV) and 3 categories 
of recommendations for clinical practice (A, B and C). 
The aforementioned levels of the quality of evidence 
and categories of recommendations (detailed in Table 
1) are used in the studies of PTOK devoted to particular 
neoplasms and methods of diagnostic and therapeutic 
management. Epidemiological conditions and the evolu-
tion of the possibilities of diagnosing and treating disease 
in oncology justify the use of reliable scientific evidence, 
which is the basis for guidelines development. The gu-
idelines provide the basis for increasing the availability 
of medically and economically sound management.
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Table 1. Evidence quality levels and recommendation categories according to the Polish Society of Clinical Oncology
Evidence quality levels Recommendation categories 
I — evidence from well-designed and conducted randomized 
controlled trials (RCTs) or meta-analysis of RCTs
II — evidence from well-designed and conducted prospective 
observational studies
III — evidence from retrospective observational or case-control 
studies
IV — evidence from clinical practice and/or expert opinion
A — indications clearly confirmed and absolutely useful in  
 clinical practice
B — indications likely and potentially useful in clinical practice
C — indications determined individually
2. Epidemiology
Kidney cancer accounts for 5% of malignant neopla-
sms in men and 3% in women, and this statistic includes 
neoplasms originating from the renal cortex and some 
neoplasms originating from the urinary tract epithelium. 
Classic renal cell cancer (RCC), originating from the 
renal cortex, accounts for 80% of all kidney cancer. The 
highest incidence of RCC is reported in Western Europe 
and the United States. Overall, in the last 2 decades, the-
re has been a 2% increase in the incidence of RCC an-
nually in both worldwide and Europe. The male gender 
dominates (the male: female incidence ratio is 1.5: 1), 
and incidence peaks around age 60–70. according 
to the National Cancer Registry, in recent years in 
Poland, there are about 5,000 cases of RCC annually 
(men — about 3,000, women — about 2,000 cases), and 
about 2,500 patients die from kidney cancer each year 
(1,500 and 1,000 patients, respectively).
3. Etiopathogenesis
Kidney cancer occurs most frequently sporadically, 
and only 2–3% of cases are associated with some family 
conditions. The exact etiology of sporadic RCC has not 
been established, however, a higher incidence of RCC has 
been associated with nicotinism, obesity, and hyperten-
sion. In turn, consumption of coffee containing caffeine 
reduces the risk of RCC, and decaffeinated coffee incre-
ases the risk of developing clear cell RCC [4]. Renal cell 
carcinoma is also more common in patients with chronic 
kidney disease, dialyzed, undergoing kidney transplanta-
tion or in patients with tuberous sclerosis complex (TSC).
Genetic factors associated with an increased risk of 
developing RCC are primarily inactivating mutations 
of the von Hippel-Lindau (VHL) gene, determining the 
development of clear cell RCC. Autosomal dominant 
inherited von Hippel-Lindau disease with germline 
VHL mutations is associated with RCC, central nervous 
system (CNS) hemangiomas, adrenal medulla tumors 
and retinal hemangiomas. In turn, mutations in the BHD 
gene are associated with the occurrence of chromophobe 
RCC (CRCC) and eosinophilic adenoma (oncocytoma), 
and the MET and FH genes mutations — papillary car-
cinomas, type 1 and 2, respectively. The list of the most 
important hereditary syndromes associated with the 
occurrence of renal cell cancers is presented in Table 2.
4. Pathology
RCC subtypes arise from different parts of the 
nephron: proximal tubule — papillary carcinoma and 
clear cell carcinoma, distal tubule — oncocytoma 
and chromophobe tumor, collecting ducts of Bellini 
Table 2. The most important hereditary syndromes associated with renal cell cancer
Syndrome  Gen Morphological features
Von Hippel-Lindau syndrome VHL Clear cell carcinoma
Hereditary papillary renal carcinoma (HPRC) MET Papillary carcinoma, type 1
Hereditary leiomyomatosis and renal cell cancer (HLRCC) FH Papillary carcinoma, type 2
Birt-Hogg-Dubé syndrome FLCN Chromophobe carcinoma or oncocytoma
Tuberous sclerosis TSC1/2 Clear cell, papillary, or chromophobe carcinoma 
Cowden syndrome PTEN Clear cell, papillary, or chromophobe carcinoma 
Hereditary pheochromocytoma syndrome (PCC) SDH 
B/C/D
Clear cell carcinoma
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— collecting duct carcinoma, renal medulla — renal 
medullary carcinoma (RMC). Clear cell RCC (ccRCC) 
accounts for 80% of kidney malignancies in adults, and 
the remaining 20% comprises a number of histological 
subtypes characterized by distinct different molecular, 
histological and cytogenetic features. Papillary and 
chromophobe carcinomas consist of 80% of non-clear 
cell carcinomas.
Clear cell renal cell carcinoma (ccRCC) — charac-
terized by the presence of cells with abundant, bright 
cytoplasm, resulting from fats and glycogen depo-
sits. A characteristic feature of ccRCC is the inactivation 
of the VHL gene, which is detected in 90% of tumors.
Papillary renal cell carcinoma — is the second most 
common histological subtype of RCC and in 10% of 
cases is bilateral. In microscopic evaluation papillary 
or tubulo-papillary structures, foci of calcification and 
necrosis are visible. Type 2 tumors are more aggressive 
(Fuhrman grade 2/3) and diagnosed at a higher stage.
Chromophobe renal cell carcinoma — cancer cells 
often with double nuclei surrounded by a characteristic 
halo. This tumor metastasizes relatively rarely, even 
when it is detected at significantly high stage (except 
the cases of sarcomatous transformation).
Collecting duct renal cell carcinoma — characteri-
stic features include tubulo-papillary structure, a fibrotic 
stroma and mucinous content. This is highly aggressive 
neoplasm malignant, with often synchronous metastases 
at diagnosis. In 22% of cases, characteristic lymphocyte-
-rich infiltrates are observed.
Renal medullary carcinoma — is rare cancer that 
occurs most frequently in young black men with hemo-
globinopathies and is more common in the right kidney 
for unknown reasons. It is associated with a very poor 
prognosis. Cancer cells are poorly differentiated, with 
eosinophilic cytoplasm. To date, less than 200 cases of 
renal medullary carcinoma have been described.
Microphthalmia-associated transcription factor 
(MiT) family translocational renal cell carcinoma — is 
characterized by the presence of translocations of genes 
encoding TFE3 and TFEB transcription factors, located 
on Xp11 and 6p11 chromosomes. This subtype is found 
in young people, more often in women. Tumors with 
translocation are very aggressive and associated with 
early lymph nodes involvement. Macroscopically, tumors 
are similar to clear cell carcinoma, with cells with very 
abundant, bright, granular cytoplasm, forming papillary 
systems or nests. However, these neoplasms are much 
less responsive to treatment compared to ccRCC.
Eosinophilic adenoma (oncocytoma) —is a benign 
tumor, accounting for 25% of small (< 3 cm) kidney 
tumors. In imaging diagnostics it is difficult to differen-
tiate from renal cell carcinoma, and in the microscopic 
evaluation of biopsy material — from chromophobe 
carcinoma. Until recently, it was believed that due to 
the possible coexistence of RCC, the diagnosis of on-
cocytoma based on biopsy sample evaluation was not 
sufficient to exclude the malignant lesion. Recent studies 
have shown that the majority of complex (hybrid) tumors 
are associated with congenital genetic syndromes. Only 
less than 5% of sporadic monofocal oncocytomas have 
complex histologic structure.
According to the International Society of Urological 
Pathology (ISUP), WHO (2016) and the Polish Society 
of Pathologists recommendations, histopathological 
diagnostics of kidney tumors should include:
 — tumor histological type;
 — the degree of differentiation according to the Fuhr-
man grading system with ISUP modification (G1–4);
 — presence of sarcomatous transformation (always 
G4 according to ISUP);
presence of necrosis;
 — presence of vascular invasion;
 — pathological stage according to pTNM (pathological 
tumor, node, metastasis) classification;
 — surgical margin;
 — description of non-neoplastic kidney tissue.
5. Diagnostics
Currently, the historical Virchow’s triad, including 
hematuria, back pain in the lumbar region, and the pre-
sence of a tumor palpable through the abdominal wall, is 
rarely found in clinical practice. If present, the Virchow’s 
triad indicates advanced or aggressive disease. In 30% 
of patients, atypical symptoms may be a consequence of 
the paraneoplastic syndrome. Now, most renal cancers 
are detected accidentally in imaging studies performed 
for other reasons. In the case of clearly suspicious results 
of imaging examinations (computed tomography — CT 
or magnetic resonance imagination — MRI), a biopsy 
prior to surgery is not necessary, but this examination 
should be performed when surgery is abandoned and 
systemic treatment is planned. Considering the fact that 
in approximately 25% of patients renal cancer will be 
diagnosed with distant metastasis, systematic staging 
is necessary already at diagnosis. This is particularly 
important due to the increasingly strong conditions for 
metastasectomy and the emerging controversy regarding 
the benefits of nephrectomy in patients with metastatic 




Computed tomography is the most important me-
thod of imaging diagnostics in RCC patients. A typical 
CT finding in this tumor type is contrast enhancement 
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Table 3. Diagnostic tests in renal cell cancer
Baseline tests in renal cell cancer
 — Abdomen ± pelvis and chest CT
 — General blood tests
 — Urinalysis
Additional tests in specific clinical situations
 — Abdomen ± pelvis MRI
• Contraindications for contrast-enhanced CT
• The need to exclude venous vessels infiltration
 — Contrast-enhanced ultrasound (CEUS)
• Evaluation of a small or unclear lesion in the kidney
• Assessment of tumor thrombus extension
 — Urine cytology, ureteroscopy, biopsy
• suspicion of pelvicalyceal system tumor
 — MRI of central nervous system (CNDS)
• Clinical suspicion of CNS dissemination
 — Bone imaging (scintigraphy or in some cases PET-CT)
• Clinical suspicion of bone dissemination
 — Biopsy (preferably core needle)
• Primary tumor — when a nephrectomy is not planned
• Metastatic lesions — in case of diagnostic doubts
 — Kidney scintigraphy
• Decreased GFR for elective nephrectomy or
• The need for a careful assessment of active renal 
parenchyma (patient with a single kidney, multifocal 
disease)
 — Genetic tests
• Genetic syndrome suspected.
CT — computed tomography; GFR — glomerular filtration rate; MR — ma-
gnetic resonance imagination; PET — positron emission tomography; PET-CT 
— positron emission tomography-computed tomography; US — ultrasound
[5] — a lesion is considered to show enhancement if the 
radiodensity difference between pre- and post-contrast 
images is at least 20 Hounsfield units (HU); increase by 
10–20 HU is considered ambiguous and requires further 
evaluation (MRI, control CT). In small tumors, the 
contrast enhancement is usually homogeneous, while 
in large tumors it is heterogeneous due to the presence 
of necrosis and hemorrhage. Despite the high accuracy 
in RCC diagnostics, CT may sometimes not be able to 
reliably distinguish cancer from eosinophilic adenoma 
(oncocytoma) [6]. In addition, in some cases, RCC shows 
very small foci of adipose tissue, which could preclude to 
reliably distinguish cancer from low-fat angiomyolipoma 
(AML) on CT scan [7]. On the other hand, the presence 
of minor calcifications/ossifications in the vicinity of 
adipose tissue foci is characteristic for cancer.
The risk of malignancy in cystic renal lesion visible 
in CT is stratified according to Bosniak classification 
[8] (Table 4). It enables the identification of “clearly 
benign” lesions (categories I, II), “probably benign” 
lesions requiring further control (IIF), lesions of an 
indeterminate nature (III) requiring surgery or active 
surveillance, and typical “clearly malignant” lesions (IV) 
requiring only surgery.
Both locally recurrent lesions and RCC distant 
metastases usually show high contrast enhancement on 
CT scans and progressive enlargement in subsequent 
examinations. Bone metastases are usually osteolytic 
— they are visible on CT as foci/areas of bone destruc-
tion. In the course of therapy, the nature of metastatic 
lesions may change from osteolytic to osteosclerotic, 
with possible enlargement. Such an image, however, 
may correspond to the focal reconstruction and reactive 
formation of bone tissue in the course of therapy, and 
not the progression, which must be taken into account 
during the radiological evaluation of the CT scan.
In the course of therapy, minor osteosclerotic 
metastatic lesions may also appear in locations where 
previously no changes were found. This may be the 
result of a reactive bone tissue reaction in the topogra-
phy of previously present metastatic lesions in the bone 
marrow, which, however, were too small to cause bone 
destruction visible on CT.
5.1.2. Magnetic resonance imaging
Kidney cancer in T1-weighted MRI images is often 
isointense (approx. 60%), possibly hypointense. In T2-
-weighted images, clear cell carcinoma usually shows 
an increased signal, while papillary carcinoma — a de-
creased signal, which allows for preliminary determina-
tion of the histological subtype already in the imaging 
examination; in addition, papillary carcinoma is often 
characterized by the presence of a pseudocapsule. 
Diffusion weighted imaging (DWI) within neoplastic 
tissue usually shows diffusion restriction. However, in 
the case of kidney tumors, DWI has a moderate accu-
racy in differentiating between malignant and benign 
lesions [9]. In some cases, MRI can better than CT 
imaging the involvement of the venous vessels, espe-
cially the extent and nature (thrombus/tumor tissue) 
of the plug in inferior vena cava (IVC) [10]. MRI can 
also be used instead of CT in case of contraindications 
to the administration of iodinated contrast agents used 
in CT and pregnant women [11]. It is estimated that 
MRI is more accurate than CT in the assessment of 
cystic kidney lesions in categories IIF and III according 
to Bosniak, therefore it can be used in case of doubt 
in the assessment of CT [12]. MRI may also be the 
preferred imaging method in young patients with con-
cerns about the use of X-rays, especially when multiple 
control assessments are required [13]. In MRI imaging 
an intravenous contrast agent containing gadolinium is 
used, which is contraindicated in the case of significant 
renal failure due to the risk of developing nephrogenic 
systemic fibrosis (NSF) [14].
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Table 4. The Bosniak classification system of renal cystic masses
Category Description Risk of  
malignancy
Management
I A simple, benign cyst with a hairline-thin wall
No visible calcifications, septa or solid 
elements. No contrast enhancement and 
homogeneous simple fluid [< 20 Hounsfield 
units (HU)]
0% Treatment usually not required. Re-assessment 
may be considered after 6–12 months to verify 
the diagnosis.
II A benign cyst with thin septum
May contain few hairline-thin septa without 
measurable contrast enhancement and fine 
calcification in the wall or septa. This category 
also includes homogeneous, well-defined, 
markedly hyperintense cysts ≤ 3 cm in diameter, 
without contrast enhancement
0–10%  Treatment usually not required. Re-assessment 




Cyst not meeting all category II criteria. 
A well-defined lesion with features requiring 
further observation
May contain many hairline-thin or minimally 
thickened septa, with discrete — perceived 
but not measurable — contrast enhancement, 
thicker or nodular calcifications of walls or 
partitions. This category also includes markedly 
hyperintense intrarenal cysts > 3 cm in 
diameter, without contrast enhancement
4.7–24% Extension of diagnostics is necessary
Access to previous imaging studies to assess 
dynamics
MRI consideration 
Thereby, observation every 3–6 months, and 
every year if a stable image is confirmed
III Indeterminate lesions that usually require 
surgery, but a significant part of them turns 
out to be mild 
With thickened or irregular wall or septa, with 
measurable contrast enhancement
40–60% Surgical treatment is usually indicated. In case 
of contraindications, fine needle biopsy or active 
surveillance may be considered
IV Usually malignant lesions
All category III criteria and a contrast-enhanced soft-
tissue component independent of the wall or septa
85–100% Surgical treatment
5.1.3. Ultrasonography
Ultrasonography (US) is the most frequently used 
method of imaging diagnostics of the abdominal cavity 
organs, including the kidneys, therefore it is often the 
first examination to find focal lesions in the kidneys, 
including accidentally — without any connection with 
the underlying disorder being the indication to US 
examination. In the RCC assessment, ultrasound is 
characterized by a much lower sensitivity and specifi-
city than CT or MRI: ultrasound detects approx. 85% 
of kidney cancers > 3 cm in diameter, but only up to 
60% of lesions < 2 cm; some of the suspected lesions 
in ultrasound are verified in CT as pseudotumors [hy-
pertrophic column of Bertin (HCB), dromedary hump). 
Renal cell carcinoma in approximately 48% of cases is 
hyperechoic, in 42% of cases isoechogenic, and 10% 
of cases hypoechoic mass. Small lesions usually show 
a homogeneous echogram, and the larger ones, similar 
to on CT, heterogeneous structure related to necrosis 
and bleeding foci; some of the lesions may show a pre-
sence of pseudocapsule.
5.1.4. Radiography
Conventional X-ray examination of bone and chest 
structures can be used as a method of the initial asses-
sment of metastatic lesions, but then diagnostics should 
be continued with more advanced techniques (CT).
5.1.5. Bone scintigraphy
Technetium-99m-methyl diphosphonate (99mTc 
— MDP) scintigraphy is a nuclear medicine technique 
that has been available for many years and allows for 
the simultaneous assessment of the entire skeleton, 
including the search for metastatic lesions. However, 
in the case of RCC, such lesions are usually osteolytic, 
which significantly reduces the sensitivity of scintigraphy, 
indicating the osteoblastic bone reaction to neoplastic 
tissue [15].
5.1.6. PET-CT
The use of positron emission tomography (PET) 
combined with computed tomography (PET-CT) in 
the diagnosis of kidney cancer is quite limited [16] 
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— compared to other cancers, RCC may not exhibit 
significant accumulation of the tracer most commonly 
used in PET — deoxy-glucose labelled with the isotope 
18F (FDG), which forces the use of other markers — 11C 
or 18F-labeled choline or acetate.
Recommendations
 — In the detection and staging of RCC, contrast-
-enhanced multiphase abdominal and thoracic CT 
should be used (invasion, tumor plug and metastatic 
lesions) (II, A).
 — Due to the slightly higher sensitivity and specificity of 
MRI compared to CT in neoplastic plugs detection, 
MRI should be performed to better assess venous 
involvement, and to reduce total radiation exposure 
or to avoid administration of an intravenous contrast 
agent used in CT (II, A).
 — Contrast-enhanced ultrasound (CEUS) is highly 
sensitive and specific in the assessment of kidney 
abnormalities. Therefore, it can be used to further 
assess small kidney lesions, neoplastic plug and dif-
ferentiate of unclear kidney lesions without the need 
for exposure to ionizing radiation (II, A).
 — PET-CT and scintigraphy are characterized by low 
sensitivity and specificity in the detection and staging 
of RCC, and therefore should not be routinely used 
in RCC staging (II, B).
6. Staging and prognostic factors 
assessment
Clinical stage is the single strongest prognostic factor 
in renal cell cancer. Five-year survival rates are at the 
level of 81%, 73%, 53%, and 8% for grades I, II, III and 
IV according to TNM, respectively [17].
Anatomical cancer staging should consider the risk 
factors that are not included in the TNM classification. 
For stages I/II, infiltration of the renal collecting system 
is a strong negative prognostic factor [hazard ratio (HR) 
3.2; 95% confidence interval (CI) 1.4–7.1] [18]. In stage 
III, the infiltration of the renal collecting system also 
seems to be a negative prognostic factor (HR 1.49; 95% 
CI 1.02–2.17) [19]. For stage III, prognostic significance 
has not been established for the presence of perirenal 
fat infiltration [20].
Due to the potential benefits of local treatment in 
oligometastatic disease [21], it is also necessary to per-
form a detailed staging in patients with stage IV disease. 
This may allow the selection of a group of patients who 
may benefit from this local treatment.
The current staging assessment guidelines are inclu-
ded in the 8th Edition of the American Joint Committee 
on Cancer/Union for International Cancer Control 
(AJCC/UICC) TNM classification 2017 (Table 5).
6.1. Histological subtype
The role of RCC histological subtype as an in-
dependent prognostic factor is debatable, especially 
when taking into account the impact of other variables, 
however, most analyzes have shown that patients with 
cancer have a worse prognosis compared to patients 
with chromophobe and papillary subtypes. Some 
less frequent subtypes, such as medullary carcinoma, 
collecting duct carcinoma, and renal cell carcinoma 
with Xp11.2 translocation, are considered the most 
aggressive. Additionally, the presence of the sarcoma-
tous component is an independent negative prognostic 
factor increasing the aggressiveness and risk of tumor 
dissemination.
The malignancy grade is also an independent pro-
gnostic factor, from many years assessed according to 
Fuhrman scale. The 5-year survival rates for grade 1, 
2, and 3/4 were 89%, 65%, and 46%, respectively [22]. 
The presence of necrosis is an additional unfavorable 
prognostic factor for clear cell and chromophobe car-
cinomas [23].
6.2. Molecular biomarkers
Different molecular markers have been assessed in 
RCC patients, including carbonic anhydrase IX (CAIX), 
hypoxia-inducible factor 1a (HIF1a), Ki67 prolife-
ration index and 9p chromosome deletion; however, 
any of them did not affect the accuracy of prognostic 
models. Currently, none of the described molecular 
markers are used in clinical practice.
6.3. Clinical factors
The prognostic impact was described for other fac-
tors, such as performance status (PS), the presence of 
cancer symptoms (fever, weight loss), paraneoplastic 
syndromes, obesity, laboratory abnormalities (anemia, 
thrombocytosis, hypercalcemia), systemic inflammato-
ry reaction (CRP, C-reactive protein), neutrophil-lym-
phocyte ratio (NLR). Based on these observations, 
numerous models and nomograms were developed and 
validated for the comprehensive analysis of indepen-
dent prognostic factors in order to assess the risk of 
recurrence in patients after radical treatment of RCC. 
However, the use of UISS system (UCLA Integrated 
Staging System) [TNM, ECOG (Eastern Cooperative 
Oncology Group) PS, Fuhrman scale], SSIGN (Stage, 
Size, Grade, and Necrosis Score) or the Karakiewicz 
nomogram (TNM, tumor symptoms, Fuhrman scale, 
tumor size) in making therapeutic decisions is limited 
due to the lack of adjuvant treatment options and the 
lack of the highest level data on optimal follow-up after 
treatment.
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Table 5. TNM classification of RCC staging according to AJCC/UICC, 8th edition
T — primary tumor
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor ≤ 7 cm in greatest dimension, limited to the kidney
T1a Tumor ≤ 4 cm in greatest dimension, limited to the kidney
T1b Tumor > 4 cm but ≤ 7 cm in greatest dimension, limited to the kidney
T2 Tumor > 7 cm in greatest dimension, limited to the kidney
T2a Tumor > 7 cm but ≤ 10 cm in greatest dimension, limited to the kidney
T2b Tumor > 10 cm, limited to the kidney
T3 Tumor extends into major veins or perinephric tissues but not into the ipsilateral adrenal gland and not beyond the 
Gerota fascia
T3a Tumor grossly extends into the renal vein or its segmental (muscle-containing) branches, or tumor invades perirenal and/
or renal sinus fat but not beyond the Gerota fascia
T3b Tumor grossly extends into the vena cava below the diaphragm
T3c Tumor grossly extends into the vena cava above the diaphragm or invades the wall of the vena cava
T4 Tumor invades beyond the Gerota fascia (including contiguous extension into the ipsilateral adrenal gland)
N — regional lymph node
Hilar, abdominal periaortic and vena cava lymph nodes. Category N is not affected by the side with the nodes
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in regional lymph node(s)
M — distant metastasis
M0 No distant metastasis
M1 Distant metastasis
Clinical staging
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage III T3 N0 M0
T1, T2, T3 N1 M0
Stage IV T4 Any N M0
Any T Any N M1
6.4. Prognostic factors in metastatic renal cell 
carcinoma
In the case of stage IV RCC, in which the patient’s 
assignment to one of the prognostic groups is the basis 
for qualification for systemic treatment, it is currently re-
commended to use the IMDC (International Metastatic 
RCC Database Consortium) prognostic model (Table 
6), but it should be remembered that in the majority 
of systemic therapies available in Poland, qualification 
for treatment is based on the older MSKCC (Memorial 
Sloan Kettering Cancer Center) criteria. The accuracy 
of these scales has been validated, but it should be 
remembered that the MSKCC is based on database 
dedicated to interferon-alpha (IFN-a) effectiveness, 
and the IMDC scale is based on data on the use of 
anti-angiogenic therapies, hence their nature may not 
keep up with the rapidly changing treatment landscape 
of generalized kidney cancer.
7. Treatment
7.1. Management of localized RCC
7.1.1. Active surveillance
Elderly patients or patients with comorbidities and 
a small kidney tumor have a relatively low risk of RCC-
-related death compared to the risk of death from other 
causes [27, 28]. Therefore, in such patients, it is advi-
sable to use active surveillance (AS), which consists in 
monitoring the disease with the use of available imaging 
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Table 6. The prognostic scales in RCC
MSKCC scale (developed on the basis of studies with IFN-a) [24]
Risk factors Prognostic  
category 
Median overall s 
urvival (months)
 — Karnofsky performance status score < 80% Favorable: 0 factors 30
 — Time from diagnosis to systemic treatment < 1-year Intermediate: 1–2 factors 14
 — Hemoglobin level < LLN Unfavorable: ≥ 3 factors 5
 — Corrected calcium concentration > ULN
 — Lactate dehydrogenase (LDH) concentration > ULN
IMDC scale (developed on the basis of studies with TKI-VEGFR) [25, 26]
Risk factors Prognostic  
category 
Median overall s 
urvival (months): first-line [25]; 
second line [26]
 — Karnofsky performance status score < 80% Favorable: 0 factors 43.2; 35.3
 — Time from diagnosis to systemic treatment < 1 year Intermediate: 1–2 factors 22.5; 16.6
 — Hemoglobin level < LLN Unfavorable: ≥ 3 factors 7.8; 5.4
 — Corrected calcium concentration > ULN
 — Neutrophil count > ULN
 — Platelets count > ULN
LLN — the lower limit of normal; ULN — lower limit of normal
tests (USG, CT or MRI) and possible implementation 
of oncological treatment in the case of a clearly progres-
sed neoplastic process. The growth rate of kidney tumors 
is usually slow, and generalization of the disease is rarely 
observed during AS [29]. In 2015, the results of a prospec-
tive, multicenter study on AS in patients with incidentally 
detected kidney tumors DISSRM (Delayed Intervention 
and Surveillance for Small Renal Masses) were published 
[30]. Almost 500 patients with kidney tumors <4 cm par-
ticipated in the study and were qualified for either surgery 
or AS. Patients assigned to AS group were usually older 
and had worse PS, more comorbidities, smaller tumors and 
more often multifocal or bilateral lesions. The tumor growth 
dynamics in the AS population was (median) 0.09 cm/year 
and decreased with the follow-up. None of the patients with 
AS died, and none developed metastatic disease. The per-
centage of patients surviving 2 and 5 years was 98% and 92% 
(surgical treatment) and 96% and 75% (AS), respectively, 
and there were no statistically significant differences. Mo-
reover, the 5-year cancer-specific survival rates were 99% 
(surgical treatment) and 100% (AS) [30, 31].
Active surveillance should be distinguished from 
close monitoring, i.e. management of patients with 
contraindications to oncological treatment, in whom 
diagnostic imaging should be carried out only in case 
of clinical indications.
7.1.2. Ablative methods
One of the treatment modalities for small renal 
masses (SRM) is a thermal ablation in the form of cry-
oablation (CA) or radiofrequency ablation (RFA). The 
evidence regarding the effectiveness of thermal ablation 
methods in the treatment of SRM come mainly from 
retrospective studies and systematic reviews.
7.1.2.1. Cryoablation (CA)
Cryoablation can be performed by both percutane-
ous and laparoscopic methods. The available — mainly 
retrospective — studies comparing the two techniques 
do not indicate any advantage of either of them in terms 
of perioperative as well as oncological outcomes, except 
for a shorter hospitalization time with the use of percuta-
neous method [32, 33]. The results of studies comparing 
nephron sparing surgery (NSS) performed by different 
techniques (open, laparoscopic or robot-assisted) with 
CA of kidney tumor (percutaneous or laparoscopic 
technique) are inconclusive. Some of them show no dif-
ferences in overall survival (OS), cancer specific survival 
(CSS), recurrence-free survival (RFS) and disease-free 
survival (DFS), local recurrence rate of progression to 
metastatic disease [34, 35], while others demonstrate 
the advantage of NSS [36, 37]. Importantly, none of 
the published studies indicates a prognostic advantage 
of CA over NSS. Studies comparing the perioperative 
NSS and CA outcomes are also inconclusive. Some of 
them show shorter hospitalization time and lower blood 
loss in patients undergoing CA [34, 35], with no diffe-
rences in other perioperative outcomes, such as recovery 
time, complication rate, postoperative serum creatinine 
concentration. Based on the available studies, it is not 
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possible to assess which of these methods is associated 
with a lower risk of developing a newly diagnosed chro-
nic kidney disease.
7.1.2.2. Radiofrequency ablation (RFA)
As with CA, RFA can be performed either percu-
taneously or laparoscopically. Both techniques show 
no differences in both the complication rate and on-
cological outcomes [38–40]. One study found a higher 
percentage of incomplete ablations with percutaneous 
access than with laparoscopic method [41]. The results 
of studies comparing RFA and NSS are inconclusive. 
One study showed comparable OS and CSS for both 
treatment methods [42]. Another study, on the other 
hand, suggests improved OS in patients undergoing 
NSS, but those patients were younger [43]. A systematic 
review [44] showed a higher local recurrence rate for 
RFA compared to NSS, with no difference in terms of 
distant metastases. A 2018 systematic review comparing 
thermal ablation (RFA or CA) with NSS showed higher 
total mortality and cancer-specific mortality for ablation 
methods, with no difference in the risk of metastasis 
and local recurrence [45]. The RFA and NSS methods 
show no differences in the complication rates and the 
postoperative glomerular filtration rate (GFR) [44], 
while a systematic review comparing ablative techniques 
(RFA or CA) with NSS showed a lower complication 
rate and a lower GRF reduction for ablation methods 
[45]. The available studies comparing RFA and CA 
[46, 47] show comparable OS, CSS and RFS for both 
thermal ablation techniques. The local recurrence rates 
in one of the studies are higher for RFA [47], and in the 
other for CA [46]. Postoperative complications rates are 
comparable [46].
Other ablation techniques, such as microwave, ultra-
sound, and laser ablation, are considered experimental 
in the treatment of kidney tumors due to the lack of 
sufficient scientific evidence.
Recommendations
 — Thermal ablation is an alternative to partial nephrec-
tomy in elderly and/or burdened with concomitant 
abnormalities (e.g. impaired renal function) patients 
with single T1a cortical renal tumors (III, C).
 — Prior to treatment, a tumor biopsy should be per-
formed using the thermal ablation method (IV, A).
7.1.3. Nephrectomy
7.1.3.1. Total versus partial nephrectomy
There is little evidence regarding the direct compari-
son of NSS and radical nephrectomy (RN) with respect 
to oncological outcomes, and the available evidence 
comes mainly from retrospective studies. One rando-
mized trial [48] and several retrospective series [49–51] 
found comparable results for CSS after NSS and RN in 
patients with small renal masses (pT1). Due to conflic-
ting results, the beneficial effect of NSS on OS compared 
to RN suggested in some studies remains unconfirmed 
[52–54]. A Cochrane systematic review found that NSS 
was associated with a shorter OS compared to RN in 
renal cancer limited to the kidney, while CSS and time 
to relapse and serious complication rates were similar 
[52]. In comparisons of NSS and RN the complication 
rate, length of hospital stay estimated blood loss, and 
blood product transfusions were similar [50–52, 55, 56]. 
A randomized trial showed that in patients with small 
kidney tumors and a properly functioning second kidney, 
NSS can be performed safely, with a slightly higher com-
plication rate compared to RN [57]. Partial nephrectomy 
is associated with better preservation of renal function 
than RN [55]. Some studies suggest a reduced risk of 
cardiovascular disease after NSS [55, 58]. The quality of 
life after NSS is rated higher than after RN [55].
In a systematic review and meta-analysis of studies 
comparing NSS in relation to RN, cT1b and T2 tumors 
were less likely to relapse and cancer-specific and total 
mortality were lower after NSS. For T2 tumors, NSS was 
associated with greater blood loss, a greater risk of com-
plications, a lower relapse rate, and lower cancer-specific 
mortality [59]. In a retrospective long-term, follow-up 
(LTFU) study (median 102 months) assessing survival in 
patients with renal tumors ≥ 7 cm undergoing NSS or RN, 
significantly better median OS and CSS were found [60].
7.1.3.2. Laparoscopic versus open nephrectomy
There are no randomized trials comparing the 
oncological outcomes of laparoscopic and open RN. 
A cohort study [61] and retrospective studies have shown 
that laparoscopic nephrectomy is associated with similar 
oncological outcomes in relation to open nephrectomy 
[51]. One randomized study and several non-randomized 
trials have shown that laparoscopic nephrectomy was 
associated with shorter hospitalization, less need for 
painkillers, and less blood loss (but with no difference 
in blood transfusions) compared to open nephrectomy 
[51, 62]. However, there were no differences in delayed 
complications or in postoperative quality of life, and the 
surgery duration was shorter in the case of open nephrec-
tomy. A systematic review reported fewer complications 
in patients undergoing laparoscopic RN [55]. There were 
no significant differences between the transperitoneal and 
retroperitoneal approach [63, 64]. In a systematic review, 
no significant differences were found in local recurrence 
rates between laparoscopic and robot-assisted RN [65].
7.1.3.3. Laparoscopic versus open partial nephrectomy
In centers with extensive experience in laparoscopy, 
there were no differences between open and laparo-
scopic partial nephrectomy with regard to RFS and OS 
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[66, 67]. Blood loss was lower with laparoscopic surgery, 
but there were no differences in postoperative mortality, 
thrombosis or pulmonary embolism (PE) [67, 68]. The 
duration of surgery and the duration of warm ischemia 
are longer with laparoscopy [67, 68]. Retroperitoneal 
and transperitoneal approach in laparoscopy is associated 
with similar perioperative outcomes. Simple enucleation 
is associated with similar progression-free survival (PFS) 
and CSS compared to standard NSS and RN [69]. A retro-
spective analysis comparing open, laparoscopic and robot-
-assisted NSS with a median follow-up of 5 years showed 
similar rates of local recurrences, distant metastases, and 
cancer deaths [70]. In a prospective study comparing the 
perioperative outcomes of open and robot-assisted partial 
nephrectomy, the latter was associated with less blood loss 
and shorter hospitalization stay. Other parameters were 
similar [71]. In the analysis of the results of 1800 open and 
robot-assisted NSS, a lower percentage of complications 
and transfusions, as well as, a shorter hospitalization stay 
were found in the group undergoing robot-assisted NSS 
[72]. A meta-analysis comparing the perioperative outco-
mes of robot-assisted and laparoscopic NSS found that 
conversion to open surgery and RN was less frequently 
required in the case of robotic surgery, warm ischemia time 
and hospitalization stay were shorter, and the magnitude 
of GFR changes after surgery was also smaller. There 
were no significant differences in complications, duration 
of surgery, blood loss, changes in serum creatinine levels 
after surgery, or positive surgical margins. There were 
no significant differences in complications, duration of 
surgery, blood loss, changes in serum creatinine levels 
after surgery, or positive surgical margins [73]. The studies 
suggest that the number of procedures (NSS in general/
robot-assisted NSS) performed in a clinical center (ho-
spital volume) influences outcomes in terms of surgical 
complications and margins [74, 75].
7.1.3.4. Management of positive surgical margins
Positive surgical margins are found after about 
2–8% of NSS [73], and more often in the case of forced 
indications and the presence of unfavorable pathological 
features [76, 77].
The influence of positive margins on oncological 
outcomes has not been clearly defined, however, based 
on the literature data, it can be concluded that their 
presence is not associated with a higher recurrence risk 
[78]. This is most likely due to the thermal destruction 
of tissues, including neoplastic cells, located in the im-
mediate vicinity of the surgical incision line. Therefore, 
in the case of positive margins, only closer monitoring 
is recommended [77, 79].
7.1.3.5. Lymphadenectomy
The indications for lymphadenectomy in patients 
without clinically suspicious lymph nodes undergoing 
NSS and RN are under discussion. Clinical evaluation 
is based on imaging studies and intraoperative palpa-
tion. The value of lymphadenectomy in patients with 
clinically unsuspected lymph nodes (cN0) was assessed 
primarily in a single randomized trial (EORTC 30881) 
[80] which showed that nodal metastases are rare (4%) 
and the benefit of extended lymphadenectomy is limited 
only to determine the degree of pathological disease 
stage. In a large retrospective study, lymphadenectomy 
in high-risk renal cancer patients was not found to be 
associated with a reduced risk of distant metastasis, can-
cer-specific and overall mortality [81]. In other studies, 
lymphadenectomy has been associated with improved 
disease-specific survival outcomes in patients with 
pN+ feature or unfavorable prognostic factors [82, 83]. 
Retrospective studies indicate that extended lymphade-
nectomy should involve the lymph nodes surrounding 
the adjacent large vessel and the area between the aorta 
and inferior vena cava (IVC). At least 15 lymph nodes 
should be removed [83].
7.1.3.6. Adrenalectomy
In a prospective, non-randomized clinical trial, 
tumor size was found to be predictive for adrenal invo-
lvement, contrary to tumor location in the upper kidney 
pole. Adrenalectomy has not been found to affect the 
prognosis of OS [84].
7.1.3.7. Embolization
There is no benefit associated with tumor emboliza-
tion prior to routine nephrectomy [85, 86]. In patients 
not eligible for surgery or with unresectable disease, 
embolization may help control symptoms (e.g. hema-
turia or pain in the lumbar region) [87].
Recommendations
 — Active surveillance should be considered in elderly 
patients with ECOG performance status ≥ 2, with 
comorbidities and a small (< 4 cm) lesion in the 
kidney (II, B).
 — Partial nephrectomy should be performed in patients 
with T1 tumors (III, B).
 — Laparoscopic radical nephrectomy should be perfor-
med in patients with T2 tumors and tumors limited 
to the kidney for whom partial nephrectomy cannot 
be performed (II, B).
 — Minimally invasive radical nephrectomy should not 
be performed in patients with T1 tumors for whom 
partial nephrectomy is possible (this includes any 
approach, including open) (II, B).
 — Minimally invasive surgery should not be performed 
if such approach may worsen oncological and func-
tional or perioperative outcomes (III, B).
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Table 7. Comparison of the most frequently used classification of kidney cancer extension














IVC 1 I 1 0 I 1
IVC < 2 cm above RV 1 II 1 II #1
IVC > 2 cm above RV and below 
HVs
1 II 1 II II 1
IVC above HVs and below the 
diaphragm
2 II 1 III III 2
IVC above the diaphragm 3 III 2 IV IV 2 or 3
IVC — inferior vena cava; RV — renal vein; HVs — hepatic veins
 — Extended lymphadenectomy should be considered in 
patients with unfavorable clinical features, including 
a large diameter of primary tumor (II, C).
 — If positive margins are found after partial nephrecto-
my, it is not recommended to extend the procedure, 
but only closer monitoring (III, C).
 — Adrenalectomy should not be performed on the 
kidney tumor side if the preoperative imaging studies 
do not reveal adrenal involvement (III, B).
 — In patients not eligible for surgical treatment with 
massive hematuria or pain in the lumbar region, 
tumor embolization should be considered (III, C).
7.2. Treatment of RCC with tumor extension
Tumor extension (TE) that grows into the lumen of 
the venous system is an unfavorable prognostic factor, 
while the outreach of tumor extension within the renal 
vein, inferior vena cava and/or cardiac cavities is not 
proportional to the risk of metastases [88] (Table 7).
Surgery is the treatment of choice in patients with 
RCC with tumor extension and without metastases, 
regardless of the outreach (level) of TE [92, 95, 96]. 
The choice of the surgical technique depends on tumor 
extension level (Table 8).
In patients with RCC with TE, minimally invasive 
surgeries are characterized by a shorter recovery time 
compared to open surgeries (including and/or sterno-
tomy with the use of extracorporeal circulation). No 
significant differences were observed in the oncologi-
cal outcomes after surgery with the use of peripheral 
cardiopulmonary circulation in deep hypothermia and 
under normothermic conditions with IVC clamping 
without supporting by extracorporeal circulation [97]. 
Preoperative embolization of the renal arteries is not 
justified, as in patients undergoing such procedure, 
a longer duration of surgery, greater blood loss, longer 
hospitalization time and higher perioperative mortality 
have been reported [97].
As in the case of RCC without TE, lymph node invo-
lvement or distant metastases in RCC patients with TE 
in the venous system is an unfavorable prognostic fac-
tor. The 5-year cancer-specific survival rate in the case 
of metastatic lymph nodes is 0–27%, while in patients 
with N0 feature it is 17–63% [98–100]. The presence of 
distant metastases in RCC patients, regardless of veno-
us system involvement by TE, is a negative prognostic 
factor. The 5-year overall survival rate in RCC patients 
with N0M0 feature, depending on the outreach of tumor 
extension, is 55% (TE limited to the sub-diaphragmatic 
inferior vena cava) or 36% (TE above the diaphragm), 
and 35% in patients with N1 or M1 feature (TE in renal 
vein), 24% (TE in IVC below the diaphragm) and 23% 
(TE above the diaphragm).
Recommendations
 — In the case of non-metastatic renal cell cancer with 
neoplastic extension growing into the lumen of the 
venous system, surgical excision of the kidney and TE 
is recommended, regardless of its outreach (II, B).
 — It is not recommended to embolize renal arteries 
prior to excision of RCC with TE growing into the 
venous system, regardless of its outreach (II, C).
7.3. Treatment of inoperable/metastatic RCC
7.3.1. Choosing the optimal strategy
When deciding on the optimal management strategy 
in patients with advanced RCC, a number of factors 
related to both the patient’s general condition and the 
features of disease should be taken into account. First, 
it is necessary to assess the possibility and justifiability 
of local treatment (primary tumor resection, resection/
radiosurgery of metastatic lesions), and only in the next 
step to consider the systemic treatment strategy (Fig. 
1). The decision regarding the introduction of systemic 
treatment must take into account stage and dynamics of 
the disease, accompanying symptoms and the possible 
presence of an immediate threat to the patient’s life, 
related, for example, to the so-called organ crisis. In the 
case of high disease dynamics, massive advancement or 
symptoms of an organ crisis, systemic treatment must 
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Table 8. Types of approaches and surgical technique depending on the outreach of kidney cancer extension (according 
to the Neves classification [92])
Incision Technique
Tumor extension level: 0
Lumbar
IVC control below and above TE
Subcostal
Middle abdominal
Possible 3- or 5-port laparoscopy
Possible robotic surgery
Tumor extension level: I
Lumbar (only for tumor of the right kidney)




Possible 3- or 5-port laparoscopy
Possible robotic surgery
Tumor extension level: II
Chevron incision
IVC control below and above TE and RV of the healthy side and performing 
thrombectomy




Tumor extension level: III
Chevron incision with a median extension




Tumor extension level: IV
Chevron incision with a median extension
Removal of TE from the right atrium using a Foley catheter, manual fingers 
technique: “up-down”, or lowering of the TE into the sub-diaphragmatic 
part of IVC
Thoracoabdominal
Middle abdominal with sternotomy
Possible laparoscopy with open atriotomy
TE — tumor extension; IVC — inferior vena cava; RV — renal vein; HVs — hepatic veins. The tumor extension level was classified by [6]
be implemented as soon as possible (even in patients 
without prior nephrectomy). In the case of patients with 
oligometastatic disease or multiple, but asymptomatic 
and potentially slowly growing metastases, especially 
located in a single site, the first delay in the introduction 
of systemic treatment and leaving the patient under 
active surveillance (AS) or referring to local treatment 
(nephrectomy, metastasectomy, stereotactic radiothera-
py of metastatic lesions) should be considered. In such 
a situation, it is possible to safely postpone systemic 
treatment for up to several months without its effecti-
veness adversely affected. The phase II study assessed 
the safety of AS in previously untreated, asymptomatic 
patients with metastatic RCC [101]. A group of 52 pa-
tients underwent control imaging examinations every 
3 months in the first year, every 4 months in the second 
year, and every 6 months in the following years. The 
median follow-up was 38.1 months, and the median 
time from the start of AS to systemic treatment was 
14.9 months. The prognostic factors suggesting the 
advantage of AS include the presence of up to one 
unfavorable prognosis factor according to the IMDC 
scale and metastases located in no more than two organ 
sites. In the group of patients with favorable prognostic 
factors, the median AS time was 22 months, while in 
patients with unfavorable factors — 8.4 months [101]. 
In any other case, adequate systemic treatment should 
be implemented (Fig. 2).
7.3.2. Cytoreductive nephrectomy
The role of cytoreductive nephrectomy (CN) in 
patients with metastatic RCC is currently the subject 
under many debates. Historically, nephrectomy in pa-
tients with metastatic RCC undergoing IFN-a-based 
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Figure 1. Management strategy in patients with advanced RCC. SBRT — stereotactic body radiation therapy; SRS — stereotactic 
radiosurgery
immunotherapy has been shown to significantly im-
prove prognosis, reducing the relative risk of death by 
more than 30% [102]. Due to this fact, primary tumor 
resection has become a standard procedure in all RCC 
patients, regardless of disease stage. Thus, at the time of 
the commencement of studies on targeted therapies in 
the treatment of RCC, the absolute majority of patients 
qualified for these studies underwent nephrectomy of 
radical or cytoreductive intent. Therefore, it was very 
difficult to conclude about the value of CN in the era of 
molecularly targeted treatment. Retrospective analysis 
of the US National Cancer Data Base, covering the 
years 2006–2013 [15.4 thousand patients treated with 
tyrosine kinase inhibitors (TKIs), including 35% of pa-
tients undergoing CN] showed that CN was associated 
with a significant reduction of the relative risk of death 
by 55% (HR 0.45; 95% CI 0.40–0.50) with OS median 
of 17.1 months (patients after CN) and 7.7 months 
(patients without CN), respectively [103].
So far, only two prospective clinical trials (CAR-
MENA and SURTIME) with incomplete recruitment 
have been conducted to assess the role of CN in patients 
with metastatic RCC receiving sunitinib [104, 105]. The 
CARMENA study verified whether systemic treat-
ment without preceding CN is non-inferior to systemic 
treatment after CN. The study included 450 patients 
(intermediate and poor prognosis according to MSKCC 
scale) randomly assigned to the experimental arm with 
CN and sunitinib or to the control arm with sunitinib 
alone. In the experimental arm, CN was performed 
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Figure 2. Systemic treatment of advanced ccRCC. TKI — tyrosine kinase inhibitors
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within 4 weeks of randomization, and sunitinib was 
administered within 3-6 weeks after CN. In the control 
arm, sunitinib was started within 3 weeks of randomi-
zation. In the intention-to-treat (ITT) population, the 
median OS (18.4 months) was not significantly higher 
in the non-CN arm than in the CN arm (13.9 months), 
which met the assumed non-inferiority boundary. In 
turn, the SURTIME study compared the effects of 
immediate and deferred CN in RCC patients receiving 
sunitinib on 28-week PFS. In a population of 99 patients 
participating in this study, no significant differences in 
relation to the indicated parameter were found, howe-
ver, a significant reduction in the relative risk of death 
was demonstrated in patients undergoing delayed CN 
(HR = 0.57; 95% CI 0.34–0.95) with a median of OS 
32.4 months (deferred CN) and 15 months (immediate 
CN), respectively. Summarizing the results of the CAR-
MENA and SURTIME studies, it can be unequivocally 
concluded that CN is not necessary in patients with 
metastatic RCC. However, a detailed analysis of the 
CARMENA study indicates that the adverse effect of 
CN on prognosis is particularly evident in the group of 
patients with ≥ 2 factors of poor prognosis according to 
IMDC scale [106]. In clinical practice, this means that 
taking into account the beneficial impact of CN on the 
immune system functions, manifested by spontaneous 
remissions or long-term disease stabilization [107, 108], 
CN is a valuable option in patients with good perfor-
mance status and tumor-related symptoms or patients 
without massive dissemination and metastases-related 
symptoms.
7.3.3. Metastasectomy
Surgical treatment or radiosurgery/stereotaxic ra-
diotherapy of metastatic lesions is an increasingly used 
procedure in the oncological treatment of patients with 
oligometastatic neoplastic disease. The basic assumption 
of such a procedure is to reduce the overall tumor mass, 
which should translate into improved prognosis. Ad-
ditionally, in many cases, local treatment may delay 
the implementation or change of systemic treatment 
strategy. First mentions of a metastasectomy (MX) in 
RCC patients appeared over 80 years ago [109]. Altho-
ugh no randomized clinical trials have been conducted 
so far, it is assumed based on numerous observational 
studies that such a procedure may improve the progno-
sis. A systematic review of 56 studies showed that the 
median OS in patients undergoing MX ranged from 
36 to 142 months compared to patients not undergoing 
MX, in whom it ranged from 8 to 27 months [110]. 
Performing MX was associated with a significant (more 
than 2-fold) reduction in the risk of death (HR 2.37; 
95% CI 2.03–2.87). The most important prognostic 
factor was the radical resection of the metastases. Other 
favorable prognostic factors were: ECOG performance 
status 0-1, clear cell histology, ISUP grade 1–2, time 
from nephrectomy to relapse > 12 months, presence of 
metastases in the lungs, pancreas, liver, thyroid gland 
and adrenal glands. Patients with metastases limited to 
the lungs had the best prognosis [110]. Radical MX of 
lung metastases compared to non-radical management 
is associated with a significant prognosis improvement 
with median OS of 69 months (radical MX) versus 
19 months (non-radical MX; P < 0.00001) and a 5-year 
CSS of 73,6% versus 19%, respectively [111]. Slightly 
worse results of surgical MX were obtained in cases of 
metastases of unusual or rare location (skin, muscles, 
salivary glands, breast, nasopharynx, stomach). In daily 
practice, it is difficult to define individual indications 
for surgical treatment of metastases. However, it can 
be assumed that before implementing systemic therapy, 
the patient should be carefully assessed in terms of the 
feasibility and benefits of MX.
Recommendations
 — Active surveillance and deferring of systemic treat-
ment may be considered in RCC patients with IMDC 
risk factor ≤ 1 and metastases in ≤ 2 organs (II, B).
 — Cytoreductive nephrectomy should be considered 
in RCC patients with synchronous metastases and 
IMDC risk factor ≤ 1 (I, B).
 — In RCC patients with synchronous metastases and 
IMDC risk factors ≥ 2 cytoreductive nephrectomy 
is contraindicated (I, B).
 — Surgical metastasectomy or radiosurgery should be 
considered in RCC patients with oligometastatic 
dissemination (II, C).
7.3.4. Adjuvant systemic therapy
The appropriateness of adjuvant systemic therapy 
after radical surgery in RCC patients has been assessed 
in numerous phase III studies. The phase III PROTECT 
study enrolled patients after radical surgery due to 
pT2, high-grade renal cell carcinoma or stage ≥ pT3 or 
pN1 RCC. Patients were randomly assigned to receive 
either pazopanib or placebo for one year. In the primary 
endpoint analysis, no significant effect of pazopanib on 
the time to disease progression was demonstrated [112]. 
The ASSURE study evaluated the effect of sorafenib or 
sunitinib treatment on DFS versus placebo. The study 
included patients without distant metastases, after rad-
ical surgery in the pT1b G3–4 N0 stage (patients with 
N0 feature were allowed to participate based on imag-
ing tests) and with higher local advancement with any 
grade and patients after radical surgery with metastatic 
lymph nodes. There were no significant differences in 
DFS [113]. The only positive study on adjuvant ccRCC 
treatment remains the phase III S-TRAC study, in which 
patients received sunitinib or placebo for one year. The 
study included 615 patients with pT3 tumor or lymph 
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node involvement after radical surgery. The median 
DFS was 6.8 years in the sunitinib group and 5.6 years 
in the placebo group, which translated into a significant 
reduction in the relative risk of disease recurrence or 
death by 24% (HR = 0.76; P = 0.03) [114]. In the sum-
mary of studies on the effectiveness of TKIs in adjuvant 
treatment, attention should be paid to the different 
inclusion criteria in individual studies. However, these 
differences and distinctness in imaging evaluation meth-
odology make it difficult to fully explain the conflicting 
results of the ASSURE and S-TRAC studies. Due to 
these doubts, the European Medicines Agency, in re-
lation to the significant toxicity of TKIs treatment, did 
not register any drug from this group for the adjuvant 
treatment of ccRCC.
7.3.5. First-line treatment for patients with clear cell RCC
7.3.5.1. VEGFR tyrosine kinase inhibitors
In patients with metastatic RCC, there are many 
systemic treatments with proven effectiveness. The eval-
uation of the studies is made difficult by the inconsistent 
application of prognostic criteria (earlier — MSKCC cri-
teria, later — IMDC criteria) — both scales distinguish 
three prognostic groups, but due to slightly different 
criteria there are some differences in the characteristics 
of patients in individual studies. Moreover, the inclusion 
criteria differed in terms of histological type. Only the 
study on the efficacy of temsirolimus included the pa-
tients with neoplasms other than clear cell carcinoma; 
other studies required to indicate clear cell histology, 
but the volume of this component in relation to the 
whole tumor was different in individual studies. Addi-
tionally, in some studies, primary tumor resection was 
required, while in others only confirmation the histolog-
ical diagnosis was sufficient. In view of the discussion 
on the role of nephrectomy in metastatic RCC, these 
differences make it difficult to compare the results of 
individual studies. Moreover, allowing the patients from 
comparative group to switch after disease progression 
to the group receiving an experimental drug (crossover) 
significantly complicates the inference regarding the 
impact of the new treatment on OS.
In older studies on the effectiveness of systemic 
treatment, the comparator was IFN-a — the first drug 
with proven effectiveness in the treatment of patients 
with metastatic RCC, but currently of historical im-
portance. In current first-line studies, the comparator 
is usually sunitinib, the first drug to be more effective 
than IFN-a.
The Phase III AVOREN study compared the com-
bination of bevacizumab and IFN-a with INF-a mono-
therapy in metastatic ccRCC. The median PFS in-
creased from 5.4 months for IFN-a to 10.2 months for 
the bevacizumab plus IFN-a combination. The median 
OS in this study did not differ significantly for both 
groups of patients, however, in the AVOREN study, 
bevacizumab + IFN-a was allowed after progression 
to IFN-a [115].
Monotherapy with sunitinib in the first-line 
treatment of advanced RCC was compared with 
IFN-a in the phase III study, which enrolled patients 
after surgical treatment of a primary tumor with dom-
inant clear cell histology from favorable and interme-
diate prognostic group according to the MSKCC scale. 
Overall survival was longer in patients treated with 
sunitinib (26.4 months) compared to those receiving 
IFN-a (21.8 months) despite sunitinib treatment in 
patients with progression in the group primary treated 
with IFN-a. The median PFS was 11 months for suni-
tinib compared with 5 months for IFN-a, which was 
also statistically significant. The objective response 
rates were 47% for sunitinib and 12% for IFN-a. All 
observed differences were statistically significant [116]. 
The results of this study ultimately resulted in the ccRCC 
treatment with IFN-a monotherapy being no longer rec-
ommended, and sunitinib becoming the first TKI used in 
first-line treatment. Another TKI used in the first-line 
treatment was pazopanib. This drug was compared with 
sunitinib in the non-inferiority phase III COMPARTZ 
study. This study demonstrated that pazopanib is not 
significantly inferior to sunitinib in terms of PFS and 
OS. The authors of the study raised the issue of better 
tolerance of pazopanib treatment [117], which to some 
extent was confirmed in the PISCES study, comparing 
patients’ treatment preferences. Patients preferred 
pazopanib (70% vs. 22%) because of less symptomatic 
toxicity associated with this drug [118]. Pazopanib is 
approved in Europe for the first-line treatment of adult 
patients with advanced RCC and for the treatment of 
patients who have previously received cytokines for 
advanced RCC.
Tivozanib was compared with sorafenib in a phase 
III study in patients with advanced ccRCC. The com-
parator used — sorafenib — raises doubts because no 
phase III study has shown its superiority to IFN-a in 
first-line treatment in terms of efficacy. Although the 
median PFS after first-line treatment was significantly 
better for tivozanib than for sorafenib (12.7 months 
vs. 9.1 months), no significant differences in OS were 
observed [119]. It was surprising that the median OS was 
higher for sorafenib (29.3 months) than for tivozanib 
(28.8 months). Tivozanib is approved for the first-line 
treatment of patients with advanced RCC, but in Poland, 
this drug is not reimbursed.
In a phase III study comparing axitinib with sorafenib 
in first-line treatment in metastatic clear cell RCC, no 
significant difference in the median PFS between the 
treatment groups was shown — as a result, axitinib was 
not registered in this indication [120].
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In the phase II CABOSUN study, which included 
157 patients with advanced RCC with intermediate and 
high risk according to IMDC, cabozantinib and sunitinib 
were compared in first-line treatment. Cabozantinib 
increased median PFS by 3.2 months (8.6 vs. 5.3 months, 
respectively), which translated into a significant re-
duction in the relative risk of disease progression or 
death by 52% (HR = 0.48; 95% CI 0.31–0.74). The 
objective response and clinical benefit rates were 20% 
and 74%, respectively, for cabozantinib, compared to 
9% and 47%, respectively, for sunitinib. Early disease 
progression occurred in 18% of patients treated with 
cabozantinib compared to 29% of patients treated with 
sunitinib. However, the CABOSUN study did not show 
an improvement in OS with cabozantinib versus suni-
tinib. Grade 3 or 4 adverse events rates were comparable 
for cabozantinib and sunitinib. Due to the limitations of 
the statistical analyzes in phase II study, the evidence is 
of lower quality and a benefit was only shown for PFS 
and objective responses [121].
7.3.5.2. mTOR kinase inhibitor
Temsirolimus — mammalian target of rapamycin 
(mTOR) serine-threonine kinase inhibitor was eval-
uated in a phase III study in patients with advanced 
RCC (also with histology other than ccRCC) with an 
unfavorable prognosis according to the MSKCC scale. 
Patients were randomized to three treatment arms: (i) 
temsirolimus monotherapy, (ii) IFN-a monotherapy, or 
(iii) temsirolimus plus IFN-a combination. Patients re-
ceiving temsirolimus achieved significantly better median 
OS and PFS than patients in the other arms. Median PFS 
and OS were 5.5 months, 4.7 months, and 3.1 months, and 
10.9 months, 8.4 months, and 7.3 months for temsiroli-
mus, IFN-a, and temsirolimus with IFN-a, respectively 
[122]. Based on this study, temsirolimus has been ap-
proved for first-line treatment in patients with advanced 
RCC with at least 3 risk factors according to MSKCC.
7.3.5.3. Checkpoint inhibitors
In the CheckMate 214 study, two-drug immuno-
therapy with immune checkpoint inhibitors (ICI): 
programmed death receptor 1 (PD-1) (nivolumab) and 
cytotoxic T cell antigen 4 (CTLA-4) (ipilimumab) was 
compared with sunitinib in patients with metastatic RCC 
containing a clear cell component. The study showed 
that immunotherapy is significantly more effective in 
patients with intermediate and unfavorable prognosis 
according to the IMDC scale (77% of participants in 
the study), and the subgroup analysis confirmed these 
results for both intermediate and unfavorable prognosis 
[123]. For patients with intermediate and unfavorable 
prognosis (considered together), median PFS was simi-
lar and accounted for 8.2 months (immunotherapy) and 
8.4 months (sunitinib), but the use of immunotherapy 
resulted in a significant reduction of the risk of pro-
gression by 23% (HR = 0.77, 95% CI 0.65–0.90). In the 
unfavorable and intermediate prognostic population 
according to IMDC, the objective response rates were 
42% and 27%, and the complete response rates were 
9% and 1% for immunotherapy and sunitinib, respec-
tively. The median OS in the immunotherapy arm was 
not reached, and in the sunitinib arm was 26.6 months, 
which translated into a significant reduction in the risk of 
death in patients with intermediate and poor prognosis 
by 34% (HR = 0.66; 95% CI 0.54–0.80). The quality of 
life in patients undergoing immunotherapy was signifi-
cantly better than that in patients receiving sunitinib. 
The improvement in prognosis after immunotherapy 
was independent of programmed death-ligand 1 (PD-
L1) expression [124]. The delay in registration of this 
treatment by the European Medicinal Agency was due 
to the unclear role of ipilimumab in combination with 
a PD-1 inhibitor and, according to the recommendation, 
a study is currently conducted that directly compares the 
value of nivolumab with or without ipilimumab. Ulti-
mately, based on the study, nivolumab in combination 
with ipilimumab has been approved in Europe for the 
first-line treatment of advanced RCC in adult patients 
with intermediate or poor prognosis.
7.3.5.4. Checkpoint inhibitors in combination with kinase 
inhibitors
In the phase III Keynote-426 study, the combination 
of axitinib and pembrolizumab with sunitinib mono-
therapy was compared in the first-line treatment of 
patients with advanced ccRCC. The study showed that 
the estimated percentage of patients who were alive at 
12 months was 89.9% in the pembrolizumab/axitinib arm 
and 78.3% in the sunitinib arm. The corresponding esti-
mates for the 18-month OS rate were 82.3% and 72.1%, 
respectively. Median OS was not reached in either 
group. The combination of pembrolizumab and axitinib 
was associated with a significant reduction in the relative 
risk of death by 47% compared with sunitinib (HR = 
0.53; 95% CI 0.38–0.74). Median PFS was 15.1 months in 
the experimental group and 11.1 months in the sunitinib 
group, which translated into a significant reduction in the 
relative risk of disease progression by 31% (HR = 0.69; 
95% CI 0.57–0.84). The benefits of pembrolizumab and 
axitinib in relation to OS and PFS were observed in all 
IMDC risk categories (however, only in the intermediate 
and unfavorable groups these differences were statisti-
cally significant), regardless of PD-L1 expression [125]. 
Based on this study, pembrolizumab in combination with 
axitinib has been approved for the first-line treatment of 
patients with advanced ccRCC.
In another phase III study, the effectiveness of 
axitinib in combination with avelumab in patients 
with metastatic RCC with a clear cell component was 
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compared with sunitinib in the first-line treatment. 
The median PFS was 13.8 months in the avelumab 
plus axitinib arm compared with 8.4 months in the 
sunitinib arm (hazard ratio of progression or death 
0.69). Among patients in the overall population with 
high, intermediate and low risk according to IMDC 
who received avelumab with axitinib, 68.1%, 51.3%, 
and 30.6%, respectively, achieved objective responses 
compared with 37.5%, 25.4 % and 11.3% of patients 
who received sunitinib. There are no data on OS in 
this study [126]. In Europe, avelumab is approved in 
combination with axitinib for the first-line treatment 
of adult patients with advanced RCC.
Recommendations
 — In patients after radical surgery due to renal cell 
carcinoma, systemic adjuvant therapy is not recom-
mended (I, A).
 — Treatment with bevacizumab in combination with 
interferon-a does not improve overall survival com-
pared to interferon- a alone and is not the treatment 
of choice (I, C).
 — Sunitinib and pazopanib are drugs of comparable 
activity in advanced renal cell carcinoma patients 
with favorable and intermediate prognosis (I, A).
 — Sunitinib and pazopanib have proven value, but in 
some patients, immunotherapy or immunotherapy 
in combination with kinase inhibitors should be 
considered first (I, B).
 — Axitinib monotherapy should not be used in the 
first-line treatment of patients with advanced renal 
cell carcinoma (I, A).
 — Cabozantinib is more active than sunitinib in the 
treatment of RCC patients in intermediate and 
unfavorable prognosis in terms of progression-free 
survival, but an effect on overall survival has not 
been proven (I, B).
 — The use of cabozantinib should be considered in 
patients with clear cell renal cell carcinoma, interme-
diate and poor prognosis, and with contraindications 
to checkpoint inhibitor-based therapies, especially 
if a rapid response is required (I, B).
 — Temsirolimus improves the prognosis of RCC pa-
tients in poor prognosis group but compared to other 
treatments the clinical benefit is very limited (I, C).
 — The use of the combination of nivolumab and ipi-
limumab in patients with renal cell carcinoma in 
intermediate and poor prognosis groups significantly 
improves the prognosis in terms of progression-free 
and overall survival compared to sunitinib (I, A).
 — The combination of pembrolizumab with axitinib in 
relation to sunitinib in patients with RCC significantly 
improves the prognosis in terms of progression-free 
and overall survival, while being associated with a very 
low risk of lack of benefit from the treatment (I, A).
7.3.6. Second-line treatment for patients with clear 
cell RCC
Historically, second-line treatment has only been 
considered in patients with advanced ccRCC after the 
failure of cytokines (e.g. IFN-a). Drugs with significant 
activity compared to placebo on PFS — but not OS 
— were sorafenib, pazopanib and axitinib. It should be 
remembered that cytokines, which are no longer used 
in practice in RCC patients, have a completely different 
mechanism of action than ICI. Therefore, the extrapo-
lation of data regarding TKIs activity after cytokines to 
their usefulness after ICIs is unjustified.
7.3.6.1. Treatment after tyrosine kinase inhibitors
The first drug with proven activity in patients 
after failure of TKI treatment was everolimus, which 
is an mTOR kinase inhibitor. In the phase III RE-
CORD-1 study, in patients who failed therapy with 
sunitinib and/or sorafenib, everolimus significantly 
increased the median PFS by 3 months (4.9 months 
versus 1.9 months) compared with placebo, reducing 
the relative risk of progression by 67% (HR = 0.33; P 
< 0.001) [127]. In this study, however, no significant 
benefit of everolimus treatment was observed in relation 
to OS (the study assumed the administration of active 
drug after progression on placebo). Although the drug 
was associated with side effects, no significant diffe-
rences in terms of patients’ quality of life were found. 
Axitinib was the first TKI with marked second-line 
treatment activity following the failure of TKI therapy. 
In the phase III study, axitinib significantly increased 
median PFS from 5.7 months to 8.3 months compared 
to sorafenib, which translated into a 35% reduction in 
the relative risk of progression (HR = 0.65; P < 0.0001). 
However, no significant differences were observed with 
regard to OS (median 19.2 months and 20.1 months, 
respectively) [128].
Significant progress in the treatment of second-line 
RCC patients occurred with the advent of nivolumab 
and cabozantinib. In parallel clinical trials, both drugs 
for the first time in history significantly increased OS 
in patients with ccRCC after failure of TKI therapy 
compared to the active comparator, everolimus [129, 
130]. In the Check-Mate 025 study, the use of nivolumab 
versus everolimus resulted in a significant reduction the 
risk of death by 27% (HR = 0.73; 95% CI 0.62–0.85) 
with no significant effect on PFS (HR = 0.88; P = 0.11). 
Nivolumab also provides a clinical benefit in 60% of 
patients with an objective response rate of 26%, howe-
ver, in over one-third of patients (35%) no benefit was 
observed from the use of nivolumab (disease progression 
at the first assessment) [130]. Nivolumab caused typical 
side effects related to the activation of autoimmune 
mechanisms, but the quality of life of patients was better 
compared to patients taking everolimus [131].
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In turn, the use of cabozantinib in the METEOR 
study compared to everolimus was associated with a si-
gnificant reduction the risk of both death — by 30% (HR 
= 0.70; 95% CI 0.58–0.85) and progression — by 42% 
(HR = 0.58; 95% CI 0.45–0.75) [129]. Cabozantinib led 
to clinical benefit in 87% of patients with an objective 
response rate of 24%, and only less than 10% of patients 
did not benefit from the treatment. Clinically significant 
side effects of cabozantinib were mainly diarrheas, which 
were more frequent and severe than for other TKIs. On 
the other hand, the profile of other side effects can 
be considered typical for this drug class. Despite the 
higher incidence of adverse events in the arm receiving 
cabozantinib, the quality of life of patients treated with 
this drug did not differ significantly in relation to evero-
limus. Additionally, the time to significant deterioration 
in the quality of life of patients was significantly longer 
for cabozantinib [132].
Currently, nivolumab and cabozantinib are the drugs 
of choice for the second-line treatment of patients with 
advanced ccRCC. Both drugs significantly improve the 
prognosis, and the drug should be selected carefully 
with regard to potential benefits and risks. The sub-
group analyzes in the study with nivolumab found that 
the drug is active in intermediate and poor prognosis 
group according to IMDC scale. As nivolumab did not 
show a significant effect on PFS, and more than 30% 
of patients will not benefit from its use, it is the optimal 
choice in patients without cachexia, asymptomatic or 
poorly symptomatic, without the risk of organ crisis, and 
not receiving antibiotic therapy within the preceding 
month. On the other hand, cabozantinib seems to be 
a better option for second-line treatment in patients 
with favorable and intermediate prognosis according 
to IMDC scale, with cancer-related symptoms and 
advanced disease, and requiring a quick and profound 
response to treatment.
7.3.6.2. Treatment after immunotherapy with nivolumab and 
ipilimumab
Due to the lack of prospective clinical trials assessing 
the effectiveness of systemic treatment of patients rece-
iving modern immunotherapy based on the combination 
of ipilimumab and nivolumab, the use of cabozantinib 
seems to be the optimal management. Retrospective 
analyzes of the METEOR study showed that cabozanti-
nib was more active than everolimus in patients receiving 
prior-line immunotherapy based on ICI.
7.3.6.3. Treatment after immunotherapy combined with 
a tyrosine kinase inhibitor
There is currently no evidence of the effectiveness of 
any systemic therapy in RCC patients after failure of ICI 
and TKI containing therapy (e.g. pembrolizumab and 
axitinib). Therefore, the procedure of choice is to enroll 
patients previously receiving such treatment for clinical 
trials. If impossible, the use of other TKIs (especially 
cabozantinib, if not used as part of combination therapy) 
or everolimus could be considered.
Recommendations
 — Cabozantinib and nivolumab are the drugs of choice 
in the second-line treatment of patients with clear 
cell renal cell carcinoma (I, A).
 — Patients who received a multi-kinase inhibitor (su-
nitinib, pazopanib) in the first line should receive 
cabozantinib (I, A) or nivolumab in the second line 
(I, A).
 — Patients who received nivolumab with ipilimumab 
in the first line should receive cabozantinib (III, B) 
or axitinib in the second line (IV, B).
 — In patients who received a combination of immuno-
therapy and a tyrosine kinase inhibitor in the first 
line, the use of another TKI (if not used as part of 
combination therapy) or everolimus may be consi-
dered in the second line (IV, C).
 — The use of cabozantinib in the second-line treat-
ment is associated with the lowest risk of treatment 
failure (I, C).
7.3.7. Third-line treatment for patients with clear cell RCC
Third-line treatment should be considered in pa-
tients in good performance status and with preserved 
organ capacity, with no contraindications to systemic 
treatment. This procedure prolongs the OS [133, 134]. 
The benefits of fourth and subsequent lines of treatment 
are limited [135–137] and should only be considered in 
selected patients. The choice of the appropriate thera-
peutic strategy depends on the clinical situation and the 
type and tolerability of previous treatment. Including 
patients in clinical trials is preferable option.
7.3.7.1. Molecularly targeted drugs
In the phase III study, which compared the efficacy 
of cabozantinib and everolimus after failure of anti-
-angiogenic treatment, 29% of patients had previously 
received two or more treatment lines (including ICI in 
nearly 5%). In this group, the efficacy of cabozantinib 
was significantly higher — the reduction in the relative 
risk of progression was 49% (HR 0.51; 0.35–0.74) [129]. 
Cabozantinib activity in the third and subsequent lines 
of treatment, including after previous ICI use, has also 
been demonstrated in retrospective studies [138, 139]. 
On the other hand, the GOLD study confirmed the 
activity of sorafenib in the third-line treatment in the 
population of patients previously treated with TKI-
-VEGFR and everolimus. The use of sorafenib was 
associated with a reduction in tumor mass in 46% of 
patients, and objective response was observed in 4% 
of patients [140].
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In the population included in the aforementioned 
RECORD-1 study, 26% of patients had previously re-
ceived two lines of TKI-VEGFR treatment (sunitinib 
and sorafenib) [127]. Everolimus was associated with an 
increase in PFS compared to placebo (median 4 months 
and 1.8 months, respectively). However, considering the 
lower activity of everolimus in relation to cabozantinib 
and nivolumab, it seems rational to use it in patients 
after failure of sequential therapy with the use of the 
above-mentioned drugs or when the above-mentioned 
drugs cannot be used.
7.3.7.2. Immunotherapy
Currently, nivolumab is the only ICI approved for 
the treatment of patients with advanced RCC after 
failure of prior therapy. In the already mentioned pi-
votal study, Check-Mate 025, 28% of patients received 
nivolumab in third-line treatment [130]. The relative 
risk of death in this group decreased by 11% (HR 0.89; 
95% CI 0.61–1.29), while a post-hoc analysis showed 
a reduction in the risk of death by 35% (HR 0,65; 95% 
CI 0.43–0.99) [141].
In fourth or subsequent treatment line, the decision 
regarding treatment strategy should be made on an in-
dividual basis, taking into account prior management, 
response to treatment, and tolerability (including persi-
stent complications of prior treatment). It is acceptable 
to use everolimus, TKI-VEGFR other than previously 
used or re-use of TKI-VEGFR, if such treatment was 
effective in the past. Re-use of immunotherapy is not 
recommended.
Recommendations
 — Third-line treatment should be considered in pa-
tients with metastatic renal cell carcinoma in good 
performance status, with no contraindications to 
systemic therapy (III, A).
 — The decision to use the fourth or subsequent treat-
ment lines should be made on an individual basis 
(IV, C).
 — Patients with metastatic renal cell carcinoma after 
sequential use of multi-kinase inhibitors should 
receive nivolumab in third-line treatment (I, B).
 — Patients with metastatic renal cell carcinoma after 
sequential treatment with a tyrosine kinase inhibitor 
and nivolumab should receive cabozantinib in third-
-line treatment (I, B).
 — In patients with metastatic renal cell carcinoma, 
sorafenib (I, B), cabozantinib (IV, B) or nivolumab 
may be used in third-line treatment after treatment 
with a multi-kinase inhibitor and everolimus.
 — Patients with metastatic renal cell carcinoma after 
sequential treatment with ipilimumab plus nivolu-
mab, followed by a multi-kinase inhibitor, should 
receive cabozantinib in third-line treatment (IV, B).
 — Patients with metastatic renal cell carcinoma after se-
quential treatment with ipilimumab plus nivolumab 
followed by cabozantinib should receive everolimus 
in third-line treatment (IV, C).
 — Patients with metastatic clear cell renal cell carcino-
ma after sequential treatment with a multi-kinase 
inhibitor combined with immunotherapy followed by 
cabozantinib should receive everolimus in third-line 
treatment (IV, C).
7.3.8. Treatment for patients with advanced non-clear 
cell RCC
Data on the effectiveness of systemic treatment of 
advanced RCCs other than clear cell histology (non-
-ccRCC) are limited. Due to their relatively rare occur-
rence, their representation in the populations of patients 
included in prospective phase III clinical trials was small 
or the protocols completely excluded the possibility of 
their recruitment. For this reason, in non-ccRCC cases, 
it is advisable to qualify patients for controlled clinical 
trials. Current knowledge about the efficacy of available 
therapeutic options in the treatment of non-ccRCC is 
based primarily on the results of small prospective stu-
dies or subgroup analyzes in larger studies that generally 
assessed the effectiveness of TKI or serine-threonine 
kinase inhibitors [142, 143].
The greatest amount of data in the non-ccRCC pa-
tient population relates to the use of sunitinib. Due to 
the design of these studies and their statistical assump-
tions, the obtained results could not provide unambigu-
ous answers regarding the efficacy of the tested drugs 
in patients with non-ccRCC; a trend suggesting the 
advantage of sunitinib over everolimus was observed. 
These data were confirmed in further expanded access 
studies, subsequent retrospective analyzes, and subgro-
up analysis in the registration process for temsirolimus.
The available data also suggest the effectiveness of 
other molecularly targeted drugs (everolimus, sorafenib, 
pazopanib, and temsirolimus), with most studies inclu-
ding only patients with papillary or chromophobe RCC. 
Recently published results of prospective clinical trials 
using ICI suggests the clinical activity of this form of 
immunotherapy in patients with non-ccRCC previously 
receiving another form of treatment.
Figure 3 presented the algorithm of first-line sys-
temic treatment developed on the basis of the above-
-mentioned studies and compliant with the ESMO 
recommendations.
Currently, there are no data based on which the 
recommendations regarding second-line systemic treat-
ment of patients with non-ccRCC could be developed. 
Nevertheless, for the most common papillary RCC, the 
use of drugs as for ccRCC is acceptable.
cMET inhibitors have shown activity in papillary 
tumors with a confirmed mutation or amplification 
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Figure 3. Management of patients with advanced non-clear cell renal cell carcinoma
in the cMET gene [144]. In turn, crizotinib and other 
cMET inhibitors may be an important alternative to 
classic TKIs with anti-angiogenic activity (anti-VEGF).
Some patients with chromophobe RCC may benefit 
from treatment with mTOR inhibitors, as it has been 
shown that mutations in chromosome 7 lead to loss of 
the functional folliculin gene and, secondly, to increased 
activity of the mTOR complex.
The available data suggest the presence of excessive 
inflammatory infiltration within tumors with sarcoma-
tous component, being a histological feature associa-
ted with poor prognosis. Renal cell carcinomas with 
a sarcomatous component appear susceptible to ICI 
therapy. In this situation, therapeutic strategies such 
as the combination of nivolumab with ipilimumab or 
pembrolizumab with axitinib should be considered as 
an option of choice [124, 125].
Due to the fact that the biology of RCC originating 
from collective ducts and medullary renal cell carcino-
mas is very similar to the biology of aggressive forms 
of cancers originating from transitional epithelial cells, 
classical chemotherapy is used in patients with these 
tumor types (e.g. MVAC regimen with cisplatin gemci-
tabine) [145–147]. Unfortunately, treatment outcomes 
for these RCC subtypes remain unsatisfactory, with 
objective response rates below 30%. There is also no 
direct comparison of the individual regimens in these 
indications [148, 149]. However, scant data on the ef-
fectiveness of immunotherapy in this group of patients 
suggest a negligible clinical benefit of the available 
therapeutic options [148].
7.3.9. Anti-osteolytic drugs
The use of zoledronic acid in RCC patients with 
multiple bone metastases is a palliative approach that 
reduces the incidence of skeletal complications and 
prolongs the time their onset without significant affec-
ting OS. Renal function monitoring is essential when 
taking zoledronic acid. Administration of zoledronic 
acid may be considered in patients with metastatic RCC 
with longer survival expected. A comparable value was 
demonstrated for denosumab.
7.4. Radiotherapy
Renal cell carcinoma is considered to be radioresi-
stant and radiotherapy is not a routinely recommended 
treatment.
Preoperative radiotherapy
The results of the only prospective studies of the 
use of preoperative radiotherapy in the treatment of 
primary operable RCC were published in the 1970s. In 
both of them, low total doses of radiation were admi-
nistered: 30 Gy in 15 fractions of 2 Gy each or 33 Gy in 
15 fractions of 2.2 Gy each using standard radiotherapy 
techniques. There has been no evidence of improvement 
in 5-year survival compared to standalone nephrectomy 
[150]. Currently, such a strategy is not recommended.
Intraoperative radiotherapy
There are only single reports of intraoperative ra-
diotherapy in RCC patients, mainly locally advanced 
or with local tumor recurrence. A study involving the 
largest group of 98 patients showed results compara-
ble to standalone nephrectomy in cancer-related and 
asymptomatic survival [151]. Due to the scarcity of data, 
intraoperative radiotherapy is not recommended and 
should only be used in clinical trials.
Postoperative radiotherapy
The role of radiotherapy in the adjuvant treatment of 
patients with locally not advanced RCC after nephrec-
tomy has not been clearly established. The experiences 
from the 1970s and 1980s showed that the treatment 
results deteriorated after adjuvant radiotherapy [152]. 
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However, studies from that period are vitiated by metho-
dological errors (e.g. small groups of incorrectly selected 
patients) and used radiotherapy techniques that did 
not allow for effective dose reduction in critical organs 
— this was a likely cause of higher toxicity of treatment 
and a lower 5-year survival rate in patients undergo-
ing radiotherapy compared to the group undergoing 
surgery alone. Later studies also failed to confirm the 
value of adjuvant radiotherapy [153]. A meta-analysis 
of data from seven studies (two prospective and five 
retrospectives) showed an increase in local cure rates 
after postoperative radiotherapy but with no effect on 
OS [154]. Coming to conclusion, postoperative radio-
therapy may be considered in patients with a high risk of 
local recurrence, mainly with positive surgical margins 
and metastases to regional lymph nodes. However, it 
should only be used in clinical trials until its value is 
confirmed in randomized trials using modern radiothe-
rapy techniques, such as intensity-modulated radiation 
therapy (IMRT).
Standalone radiotherapy
The opinion about RCC radioresistance may be 
wrong because the use of modern radiotherapy techni-
ques allows the administration of high radiation doses in 
one (stereotactic radiosurgery, SRS) or several fractions 
(stereotactic body radiotherapy, SBRT). Therefore, it 
allows also to overcome radioresistance while reducing 
the risk of damage to healthy tissues. This procedure, 
apart from direct destruction of cancer cells by activation 
of the ceramide signaling pathway, may also induce the 
so-called abscopal effect. Released products of tumor 
cell lysis become visible to the immune system, causing 
its “unmasking” and effective destruction of cancer 
cells. This effect can be enhanced by the simultaneous 
use of molecularly targeted therapies. The experience 
regarding stereotactic radiotherapy of RCC brain meta-
stases, showing local control improvement, has become 
the basis for using this method in patients with locally ad-
vanced RCC who are not eligible for nephrectomy [155]. 
Several prospective studies have shown promising 2-year 
local cure rates of over 90% with acceptable toxicity. 
The lack of evidence from randomized trials does not 
allow to determine neither the optimal dose of radiation 
nor the method of fractionation or to recommend such 
a treatment in routine clinical practice. Primary RCC 
radiosurgery and stereotactic radiotherapy should only 
be used in clinical trials.
Radiotherapy in oligometastatic disease
Many retrospective studies show improved treatment 
outcomes in patients with RCC after primary nephrec-
tomy who underwent metastasectomy, radiosurgery, 
or stereotactic radiotherapy after oligometastatic di-
sease recurrence [156, 157]. For both intracranial and 
extracranial metastases, local control rates account for 
up to 90%, and the median OS is 7 to 26 months. In 
prospective randomized studies, the effect of tumor bed 
postoperative radiosurgery on the reduction of local 
recurrence risk in patients with brain metastases after 
complete metastasectomy compared to observation was 
confirmed. Additionally, it has been shown reduced 
cognitive impairment compared with total brain irra-
diation [158, 159].
Radiosurgery and stereotactic radiotherapy are re-
commended treatment methods in patients with RCC 
brain metastases.
Achieving control of metastatic lesions in the brain 
with radiotherapy is indicated before starting anti-an-
giogenic treatment.
Palliative radiotherapy
Numerous reports indicate that radiotherapy is an 
effective method of controlling symptoms related to 
local progression or dissemination of RCC. It enables 
the reduction of pain caused by spreading to the bone 
or infiltration of nerve plexuses and managing the symp-
toms associated with multiple metastases in the brain. 
The administered total doses and applied fractionation 
methods depend mainly on patient’s performance status, 
location of metastases and the volume of irradiated 
tissues. Response to radiotherapy is achieved in more 
than 50% of patients [160, 161]. Radiotherapy is the 
method recommended for symptom control in patients 
with metastatic RCC.
Recommendations
 — Stereotactic radiotherapy is the recommended tre-
atment option in patients with renal cell carcinoma 
with metastases to the central nervous system (II, A).
 — Radiotherapy is a valuable therapeutic option in the 
symptomatic treatment of patients with metastatic 
renal cell carcinoma (III, B).
 — Stereotactic radiotherapy is an alternative to surgical 
metastasectomy (III, B).
8. Follow-up after treatment completion
The objectives of observation of RCC patients after 
the completion of surgical treatment include moni-
toring and/or diagnosing the nature of postoperative 
complications and dysfunction, as well as the detection 
of local recurrences or contralateral RCC and distant 
metastases.
There is no consensus on the post-treatment mo-
nitoring principles in RCC patients. There are also no 
prospective studies analyzing the prognosis of patients 
depending on the time of relapse diagnosis. Intensive 
surveillance with the use of imaging tests is not necessary 
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in all patients, but follow-up after treatment completion 
is warranted (especially in patients receiving treatment 
with radical intent). Large long-term cohort observatio-
nal studies are available [162, 163]. They demonstrated 
a benefit in terms of survival in patients undergoing 
a structured observation protocol compared to unobse-
rved patients [164]. The long-term results after surgery 
for low-stage tumors (T1a) are almost always excellent. 
Therefore, a gradation in the intensity of monitoring 
based on the risk of relapse and/or disease generalization 
is warranted. The risk should be determined based on the 
UCLA Integrated Staging System (UISS) for Renal Cell 
Carcinoma [165, 166] (Table 9). Therefore, personalized 
and risk-based monitoring after treatment completion 
with regular imaging examinations is currently recom-
mended (Table 10).
CT is most commonly used for oncological monito-
ring, and ultrasound is used only in some cases. PET-
-CT, PET-MR and scintigraphy are not routinely 
recommended. In low-risk patients, follow-up should 
take into account the expected benefits and exposure to 
ionizing radiation. MR imaging can be used to reduce 
Table 9. UCLA Integrated Staging System (UISS) for renal cell carcinoma
Localized disease (any T, N0, M0)
Primary tumor (T) Differentiation ECOG performance status Risk 




T3 Fuhrman 1 0
≥ 1
Fuhrman > 1 0
≥ 1 High
Metastases (N1, N2 or M1)
N1M0 Any Any Low
N2M0/M1 Fuhrman 1 0
≥ 1 Intermediate 






Stage Risk 5-year survival rate
Localized disease Low 91.1%
Intermediate 80.4%
High 54.7%
Metastatic disease Low 32%
Intermediate 19.5%
High 0%
Table 10. Schedule of follow-up of RCC patients after completion of surgical treatment
Risk profile Observation
6 months 1 year 2 years 3 years > 3 years
Low US CT US CT CT every 2 years, patient education about the 
risk of recurrence accounting for app. 10%
Intermediate/high CT CT CT CT CT every 2 years
CT — computed tomography of chest and abdomen, alternatively abdominal imaging with the use of magnetic resonance imaging; US — ultrasound of 
abdominal cavity, kidney/kidneys and/or postoperative tumor bed
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radiation exposure. Chest, abdominal and pelvic CT 
scans should be performed in patients from moderate 
or high-risk groups.
Post-treatment follow-up should also include monito-
ring of renal function, including the measurement of se-
rum creatinine concentration along with GFR. Repeated 
and long-term monitoring of upper urinary tract func-
tioning is indicated in the presence of renal dysfunction 
both before and after surgery [167]. Regular evaluation 
of cardiovascular risk factors is also recommended.
In patients undergoing partial nephrectomy, local 
disease recurrence is rare, but it is important to re-
cognize it early, due to the potential qualification for 
radical re-treatment [168, 169]. Relapse of the under-
lying disease in the second kidney is also rare (1–2%), 
and it may occur late (median 5–6 years) and may be 
associated with positive surgical margins, multifocal 
lesions, and higher histopathological grade [170]. In 
addition to early detection of local recurrence, proper 
monitoring of patients with RCC after treatment is also 
aimed at early detection of distant metastases. In late-
-diagnosed metastatic disease, local treatment options 
are usually limited (surgical metastasectomy, stereo-
tactic radiotherapy), which are the treatment of choice 
in oligometastatic disease. Furthermore, detecting 
relapse/cancer generalization with a low total tumor 
mass can increase the effectiveness of systemic therapy.
Controversies concern the optimal duration of 
observations. According to some authors, continuing 
imaging tests beyond 5 years is cost-ineffective; however, 
late metastases occur more often as single lesions, which 
justifies an aggressive treatment approach with curative 
intent. In turn, in patients with newly diagnosed tumor 
in contralateral kidney, the detection of the tumor at an 
early stage often enables nephron-sparing surgery. For 
tumors <4 cm, there is no difference between partial 
and radical nephrectomy in relation to recurrence du-
ring follow-up [171]. Currently, various nomograms are 
available to estimate the likelihood of cancer recurrence, 
metastasis development, or later death, which can be 
used in everyday clinical practice [172, 173].
Recommendations
 — The strategy for monitoring RCC patients after tre-
atment completion should be based on the relapse 
risk (III, A).
 — Patients should be closely monitored after NSS with 
a positive surgical margin or if the tumor size exceeds 
7 cm (III, C).
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